Yi Boyer Jennifer M sold $72K of INGN

Yi Boyer Jennifer M (EVP Entrprs Enblmnt, Ch HR Off) sold 10,938 shares of Inogen Inc (INGN) at $6.60 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yi Boyer Jennifer M
Published Jul 6, 2026, 8:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INGN
Neutral
high confidence
Mentioned
$INGN
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INGNNeutralLow
01

Why it matters

The disclosure quantifies the sale (10,938 shares at $6.5959) and confirms it was executed under a pre-arranged 10b5-1 plan, which typically lowers the likelihood of immediate fundamental implications.

02

Market read

Provides a concrete insider-selling datapoint for INGN, but without any new operational or guidance information.

03

What to watch

The filing does not indicate why shares were sold (taxes, diversification, scheduled liquidity), so the signal quality is limited.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-06 after-hours; reflects sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction for Inogen, reported by an EVP and HR Chief Officer.

Company-level read

Ticker impact

$INGNNeutralHigh confidence
Context

Inogen Form 4 shows EVP Jennifer M Yi Boyer sold 10,938 shares on 2026-07-01 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is an SEC Form 4 insider transaction; it provides transaction details but no new company-specific operational or financial catalyst.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with perceived valuation risk; traders may still watch for follow-on selling.

Key entities

  • Inogen Inc

    Subject of the Form 4 insider transaction; EVP and HR Chief Officer sold shares under a 10b5-1 plan.

  • Yi Boyer Jennifer M

    EVP Entrprs Enblmnt, Ch HR Off; reported the open-market sale transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INGNMed

Inogen (INGN) Q3 2026 Earnings Call Transcript

Inogen (INGN) reported Q3 2026 earnings, with total revenue at $77.2M, U.S. sales up 3.8% YoY, and international sales down 9%. The company completed a divestiture of its U.S. oxygen rental business for up to $24.8M. Adjusted net loss was $400K, and a $20M cost savings program was announced to accelerate profitability. New CEO Andrew Reding emphasized growth and operational improvements.

$INGNMed

What Inogen (INGN) Said on Its Q3 Earnings Call

Inogen (INGN) reported Q3 adjusted gross margin decline to 44.2% from 45.9% YoY, citing lower international sales. Operating expenses fell 4.4% to $35.3M. The company sold its U.S. oxygen rental business for up to $24.8M, expecting receipt in 2027. A cost-reduction program targets $20M in annualized savings by 2027. GAAP loss widened to $14.8M from $3.6M YoY. Q4 revenue forecast is $65M-$68M, with full-year revenue expected at $298M-$301M and an adjusted net loss of $7M-$8M.

$INGNMed

Inogen: Q3 Earnings Snapshot

Inogen Inc. (INGN) reported a Q3 loss of $16.2M, or 61 cents per share, with adjusted losses of 56 cents per share. Revenue was $77.2M. The company expects full-year revenue between $298M and $301M.

$INGNLow

Inogen Inc (INGN): Results of Operations and Financial Condition

Inogen Inc (INGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inogen Announces Leadership Transition Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer BEVERLY, Mass., November 5, 2026 – Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use i